News
ENEAPHARM at BIO EUROPE 2025, November 3-5, VIENNA
Sep 29, 2025
Eneapharm is delighted to take part in this leading international event, bringing together industry leaders,
Read more
Eneapharm unveils its new visual identity !
Sep 4, 2025
What’s New ? A visual identity including new revitalized logo, new color palette and new
Read more
Pancreatic insufficiency : EN311, a targeted therapeutic response
Aug 26, 2025
When the pancreas, due to mechanical issues or dysfunction, can no longer produce sufficient digestive
Read more
Eneapharm with EN311 at BIO Convention 2025 – Boston
Jun 18, 2025
We were proud to present EN311, our solution dedicated to the treatment of exocrine pancreatic
Read more
Cystic fibrosis and pancreatic function
Jun 2, 2025
A silent challenge beyond the lungs. Cystic fibrosis, also known as mucoviscidosis, is a rare
Read more
New Milestone Achieved: GMP Clinical Manufacturing Partnership for EN311 successfully Launched
May 27, 2025
We are pleased to announce our new collaboration with Skyepharma- Fully integrated CDMO, a highly
Read more
EN311 at ESPGHAN 2025
May 15, 2025
We are proud to present our exceptional results at ESPGHAN 2025 andexcited to share our
Read more
EN311 tackles what alcohol and tobacco silently damage: your pancreatic function
May 3, 2025
Everyday, people experience unexplained digestive discomfort — unaware that the root cause may be a
Read more
EN311 by Eneapharm at ESPGHAN 2025
Apr 10, 2025
We’re proud to be taking part in ESPGHAN 2025, the leading European event dedicated to
Read more